Biotech | May 19, 2022
Piramal Pharma Solutions new API plant in Canada goes online
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)